JP2021523213A5 - - Google Patents
Info
- Publication number
- JP2021523213A5 JP2021523213A5 JP2020564674A JP2020564674A JP2021523213A5 JP 2021523213 A5 JP2021523213 A5 JP 2021523213A5 JP 2020564674 A JP2020564674 A JP 2020564674A JP 2020564674 A JP2020564674 A JP 2020564674A JP 2021523213 A5 JP2021523213 A5 JP 2021523213A5
- Authority
- JP
- Japan
- Prior art keywords
- icos
- cells
- seq
- agonist
- antibody
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (9)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862671181P | 2018-05-14 | 2018-05-14 | |
| US62/671,181 | 2018-05-14 | ||
| US201862679346P | 2018-06-01 | 2018-06-01 | |
| US62/679,346 | 2018-06-01 | ||
| US201862750026P | 2018-10-24 | 2018-10-24 | |
| US62/750,026 | 2018-10-24 | ||
| US201962827312P | 2019-04-01 | 2019-04-01 | |
| US62/827,312 | 2019-04-01 | ||
| PCT/US2019/032184 WO2019222188A1 (en) | 2018-05-14 | 2019-05-14 | Methods of treating cancer |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2021523213A JP2021523213A (ja) | 2021-09-02 |
| JP2021523213A5 true JP2021523213A5 (https=) | 2022-05-20 |
Family
ID=66690990
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020564674A Pending JP2021523213A (ja) | 2018-05-14 | 2019-05-14 | 癌を治療する方法 |
Country Status (5)
| Country | Link |
|---|---|
| US (2) | US11292840B2 (https=) |
| EP (1) | EP3793598A1 (https=) |
| JP (1) | JP2021523213A (https=) |
| CN (1) | CN112703012A (https=) |
| WO (1) | WO2019222188A1 (https=) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2013059740A1 (en) | 2011-10-21 | 2013-04-25 | Foundation Medicine, Inc. | Novel alk and ntrk1 fusion molecules and uses thereof |
| US11230589B2 (en) | 2012-11-05 | 2022-01-25 | Foundation Medicine, Inc. | Fusion molecules and uses thereof |
| CA3150658A1 (en) | 2013-01-18 | 2014-07-24 | Foundation Medicine, Inc. | Methods of treating cholangiocarcinoma |
| US20200024351A1 (en) * | 2017-04-03 | 2020-01-23 | Jounce Therapeutics, Inc. | Compositions and Methods for the Treatment of Cancer |
| US20210380942A1 (en) * | 2018-10-24 | 2021-12-09 | Jounce Therapeutics, Inc. | Methods and compositions for the treatment of cancer and infectious diseases |
| US20220396839A1 (en) | 2019-11-12 | 2022-12-15 | Foundation Medicine, Inc. | Methods of detecting a fusion gene encoding a neoantigen |
| JP2023510847A (ja) * | 2020-01-13 | 2023-03-15 | ジャウンス セラピューティックス， インク． | 癌の治療方法 |
| IL297313A (en) * | 2020-04-20 | 2022-12-01 | Jounce Therapeutics Inc | Compositions and methods for vaccination and treatment of infectious diseases |
| GB202007099D0 (en) | 2020-05-14 | 2020-07-01 | Kymab Ltd | Tumour biomarkers for immunotherapy |
| CN112807425A (zh) * | 2021-01-14 | 2021-05-18 | 南方医科大学深圳医院 | 一种tTIM融合蛋白疫苗、制备方法及应用 |
| TW202313682A (zh) | 2021-05-18 | 2023-04-01 | 英商凱麥博有限公司 | 抗icos抗體之用途 |
| EP4359570A4 (en) | 2021-06-25 | 2025-04-30 | Foundation Medicine, Inc. | METHODS OF USING SOMATIC HLA-I LOH TO PREDICT RESPONSE IN IMMUNE CHECKPOINT INHIBITOR-TREATED PATIENTS WITH LUNG CANCER |
| WO2023222854A1 (en) | 2022-05-18 | 2023-11-23 | Kymab Limited | Uses of anti-icos antibodies |
| JP2025160816A (ja) * | 2024-04-10 | 2025-10-23 | イミューンオンコ バイオファーマシューティカルズ （シャンハイ） インコーポレイテッド | 古典的ホジキンリンパ腫に対する併用療法 |
| CN118516308B (zh) * | 2024-07-22 | 2024-10-22 | 深圳市中佳生物医疗科技有限公司 | 免疫调节剂在制备增强nk细胞毒性作用的产品中的应用 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US4683195A (en) | 1986-01-30 | 1987-07-28 | Cetus Corporation | Process for amplifying, detecting, and/or-cloning nucleic acid sequences |
| EP3147297B1 (en) | 2011-03-31 | 2018-12-12 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Antibodies directed against icos and uses thereof |
| CA2889182A1 (en) | 2012-10-26 | 2014-05-01 | The University Of Chicago | Synergistic combination of immunologic inhibitors for the treatment of cancer |
| EP2970114B1 (en) | 2013-03-15 | 2019-05-15 | Bristol-Myers Squibb Company | Ido inhibitors |
| RS60614B1 (sr) | 2015-03-23 | 2020-08-31 | Jounce Therapeutics Inc | Antitela za icos |
| AU2016342269A1 (en) * | 2015-10-22 | 2018-03-29 | Jounce Therapeutics, Inc. | Gene signatures for determining icos expression |
| WO2018029474A2 (en) * | 2016-08-09 | 2018-02-15 | Kymab Limited | Anti-icos antibodies |
| US11858996B2 (en) * | 2016-08-09 | 2024-01-02 | Kymab Limited | Anti-ICOS antibodies |
-
2019
- 2019-05-14 CN CN201980047070.3A patent/CN112703012A/zh active Pending
- 2019-05-14 WO PCT/US2019/032184 patent/WO2019222188A1/en not_active Ceased
- 2019-05-14 US US16/411,744 patent/US11292840B2/en active Active
- 2019-05-14 JP JP2020564674A patent/JP2021523213A/ja active Pending
- 2019-05-14 EP EP19728206.4A patent/EP3793598A1/en not_active Withdrawn
-
2022
- 2022-03-31 US US17/709,712 patent/US20220332823A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2021523213A5 (https=) | ||
| Ishikawa et al. | Phase I clinical trial of adoptive transfer of expanded natural killer cells in combination with I g G 1 antibody in patients with gastric or colorectal cancer | |
| Makita et al. | Clinical development of anti‐CD 19 chimeric antigen receptor T‐cell therapy for B‐cell non‐Hodgkin lymphoma | |
| JP6290751B2 (ja) | Ｎｋ細胞増強化合物を使用する治療抗体の有効性を増大させる方法および組成物 | |
| US20230277591A1 (en) | Use of flt3 car-t cells and flt3 inhibitors to treat acute myeloid leukemia | |
| Goldwater et al. | A phase 1, randomized ascending single-dose study of antagonist anti-human CD40 ASKP1240 in healthy subjects | |
| KR20190123749A (ko) | 항-tigit 항체 | |
| KR20150042784A (ko) | Ｃａｒ의 항-종양 활성에 대한 독성 관리 | |
| CN112739715A (zh) | 抗cd38抗体的皮下给药 | |
| CN109385403A (zh) | 靶向gpc3的car nk细胞 | |
| WO2016069589A1 (en) | Treatment of pediatric bcp-all patients with an anti-kir antibody | |
| Magalhaes et al. | CD19 chimeric antigen receptor T cells from patients with chronic lymphocytic leukemia display an elevated IFN-γ production profile | |
| Zhang et al. | Secretion of human soluble programmed cell death protein 1 by chimeric antigen receptor-modified T cells enhances anti-tumor efficacy | |
| WO2017205213A1 (en) | Combination therapy of abemaciclib and immune checkpoint modulators for use in the treatment of cancer | |
| CN113117073A (zh) | 免疫细胞联合抗体在治疗癌症中的用途 | |
| CN110520539A (zh) | 预测抗癌药的临床结果的方法 | |
| Mond et al. | SURFACE ANTIGENS OF IMMUNOCOMPETENT CELLS: III. IN VITRO STUDIES OF THE ROLE OF B AND T CELLS IN IMMUNOLOGICAL MEMORY | |
| Ma et al. | Automatic generation of lymphocyte heterogeneity: Division‐dependent changes in the expression of CD27, CCR7 and CD45 by activated human naive CD4+ T cells are independently regulated | |
| Nelson et al. | TT hybridoma product specifically suppresses tumor immunity. | |
| US20240207311A1 (en) | Tumor infiltrating lymphocytes therapy | |
| Luo et al. | Natural Killer Cell‐Mediated Antitumor Immunity: Molecular Mechanisms and Clinical Applications | |
| CN116963746A (zh) | 选择性靶向cd6高细胞并降低teff细胞的活性的方法 | |
| Batatinha et al. | Exercise-Mobilized Lymphocytes Enhance the Function of Cytokine-Induced Memory-like NK-cells Against Myeloid Leukemia | |
| Zhang et al. | Enhancement of B7-H3 chimeric antigen receptor-T cell efficacy via the coexistence effect of IL-7, IL-15 and CCL19 for pancreatic and lung xenograft tumors | |
| CN115724979B (zh) | 一种多功能重组抗体及其制备方法和应用 |